Levetiracetam Shortage: What Providers and Prescribers Need to Know in 2026

Levetiracetam remains one of the most frequently prescribed antiepileptic drugs (AEDs) in the United States, with more than 6 million annual prescriptions. While no active national FDA shortage exists for oral levetiracetam in early 2026, prescribers continue to field patient calls about stock-outs at local pharmacies—a pattern that has persisted since the major generic shortage of 2019–2020. This guide provides a practical clinical framework for managing these situations.

Current Supply Situation (2026 Update)

Oral generic levetiracetam (immediate-release tablets) is broadly available from multiple manufacturers in 2026, including Apotex, Lupin, Torrent, Sun Pharma, and Teva. The extended-release (XR) market has fewer manufacturers, making it more vulnerable to localized disruptions. The IV formulation experienced documented supply disruptions in 2024 (Hikma back order, Athenex and X-Gen discontinued production).

Despite broad market availability, just-in-time pharmacy inventory practices mean individual pharmacy locations can run out without warning. A 2024 patient survey found 62.8% of epilepsy patients had experienced difficulty finding levetiracetam—a figure that substantially exceeds what national shortage data would suggest.

Clinical Risks of Levetiracetam Gaps

Unlike many medications, missing even 1–2 doses of levetiracetam carries meaningful clinical risk for patients with epilepsy:

• Breakthrough seizures: Seizure threshold decreases rapidly when AED levels drop below therapeutic range. Patients who have been seizure-free for months or years can seize within hours of dose omission.
• Status epilepticus: Rapid AED discontinuation—even involuntary—can precipitate status epilepticus, a neurological emergency with significant morbidity and mortality.
• Loss of driving privileges: In most states, a new seizure triggers a mandatory driving restriction period (typically 3–6 months). This has significant functional and occupational consequences for patients.
• Anxiety and PTSD-like reactions: Patients living in fear of medication unavailability experience significant psychosocial impact. Proactive management reduces this burden.

Formulation Alternatives Within Levetiracetam

When one levetiracetam formulation is unavailable, consider others with distinct supply chains:

• Immediate-release tablets: 250 mg, 500 mg, 750 mg, 1000 mg. Bioequivalent dose adjustments are straightforward (e.g., two 250 mg for one 500 mg).
• Extended-release tablets (Keppra XR, Elepsia XR): Once-daily dosing; different manufacturing supply chain from IR tablets. If one is unavailable, the other may not be.
• Oral solution (100 mg/mL): Stocked separately from tablets; often available when tablets are not. Dose in mL is straightforward to calculate from mg dose.
• Orally disintegrating tablet (Spritam): A 3D-printed formulation with different supply characteristics; may be available at select pharmacies when standard tablets are not. Requires specific handling.

Alternative AED Substitution: Clinical Considerations

When levetiracetam is truly unavailable in any formulation, consider the following evidence-based alternatives, tailored to seizure type and patient profile:

• Brivaracetam (Briviact): Same SV2A mechanism; generally fewer behavioral side effects; can be cross-titrated more rapidly than most AEDs. Approved for partial-onset seizures. Monitor for withdrawal seizures during transition.
• Lamotrigine (Lamictal): Broad-spectrum; not suitable as an emergency substitute due to required slow titration (SJS risk with rapid escalation). Long-term alternative for patients who cannot take levetiracetam.
• Valproic acid / divalproex (Depakote): Broad-spectrum alternative; avoid in women of childbearing potential without adequate contraception (high teratogenicity). Monitor LFTs, CBC. Drug interactions via CYP2C9 inhibition.
• Clobazam (Onfi) as add-on: In emergency situations where the patient cannot get any levetiracetam, a short-term bridge with clobazam (schedule IV) while levetiracetam is sourced may be appropriate for select patients. Discuss with specialist.

Manufacturer Switching: What to Tell Patients

All FDA-approved generic levetiracetam products must demonstrate bioequivalence (AUC and Cmax within 80–125% of reference). In clinical practice, switching between generic manufacturers is generally safe, but some patients with epilepsy—particularly those who are seizure-free and sensitive to small pharmacokinetic variations—may notice differences in inactive ingredients (dyes, binders, fillers). Counsel patients to:

• Note the manufacturer name and NDC on their pill bottle
• Report any changes in seizure frequency or tolerability within the first 2–4 weeks of switching
• Avoid changing two variables at once (e.g., manufacturer AND dose)

Proactive Prescribing Strategies to Reduce Shortage Risk

Consider these practical prescribing adjustments to reduce your patients' exposure to shortage-related gaps:

1. Prescribe 90-day supplies where coverage allows. Mail-order pharmacies often have larger buffer stock.
2. Note "DAW 0" (dispense as written) only if there is a documented medical reason for a specific manufacturer—otherwise allow generic substitution to maximize options.
3. Educate patients to refill 7–10 days early and to contact the office if they encounter stock-outs—not just wait.
4. Recommend medfinder to patients—this service calls pharmacies to find which ones have the medication in stock, reducing the burden on both patients and your office staff. Visit medfinder.com/providers to learn more.

Summary for Clinicians

Levetiracetam supply disruptions in 2026 are primarily localized rather than national, but their clinical consequences are identical: patients with epilepsy cannot afford medication gaps. By prescribing 90-day supplies, educating patients to refill early, and directing patients to resources like medfinder, prescribers can meaningfully reduce their patients' vulnerability to these disruptions.